Search

Displaying results 1101 - 1110 of 3917 in total
  1. Drug

    Pemirolast

    go.drugbank.com/drugs/DB00885
    ApprovedWithdrawn

    Pemirolast potassium is a slightly yellow powder that is soluble in water. It is a mast cell stabilizer that acts as an antiallergic agent. As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of th...

  2. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small

  3. Drug

    Sildenafil

    go.drugbank.com/drugs/DB00203
    ApprovedInvestigational

    Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication

  4. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 3...

  5. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also c...

  6. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    marketing authorization for the treatment of adult and pediatric patients who experience EBV-associated post-transplant lymphoproliferative disorder (PTLD) following solid organ transplantation (SOT) or bone

  7. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    It has a weak inhibitory effect on GABA receptor binding sites.

  8. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  9. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  10. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.